Leadership

Kate Rumrill

President and Chief Executive Officer

Kate Rumrill is a seasoned executive, with 30 years of extensive experience in the Medical Device and Pharmaceutical Industry. She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. Most recently, Kate was the President and CEO of NeoSync, Inc., a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with Covidien’s Peripheral Vascular Division. She has extensive experience in product development and new product launches, most notably through her time at Covidien and Eli Lilly & Company. Kate holds a BS degree in both Biology and Psychology from the State University of New York.​
Lisa Mastromattei

VP, Finance

Lisa Mastromattei has over 30 years of diverse experience in Finance and Accounting, primarily in the medical device industry. Most recently, she was the VP of Finance, HR, and IT for Mitralign, a medical device company focused on treating functional mitral and tricuspid regurgitation. She is versed in strategic planning, merger and acquisitions, fundraising, and risk management. Lisa’s leadership experience also includes Global Controller at Microline Surgical and Director of Accounting at Orchard Brands. She received her BS from Suffolk University and is a certified Six Sigma Black Belt.
Jason Fortier

VP, Product Development

Jason Fortier is a medical device R&D leader with over 20 years of experience transforming innovative concepts into commercial products. He has a diverse product development background that includes work with absorbable hydrogels, combination devices, process development, preclinical research, and clinical strategy. His career includes positions at Covidien and Medtronic, as well as successful start-ups Augmenix, Confluent Surgical, and Evolved by Nature. Jason received an MS in Mechanical Engineering from MIT and a BE from Thayer School of Engineering at Dartmouth College.
Tim Fischell, MD, FACC, MSCAI, FNAI

Chief Medical Officer

A practicing interventional cardiologist, prolific inventor and entrepreneur, Dr. Tim Fischell is currently Professor of Medicine at Michigan State and Medical Director of the Borgess Heart Institute Department of Cardiovascular Research and the Interventional Cardiology Fellowship Program. An inventor and co-inventor on over 70 patented devices, he co-designed the stent upon which the J&J drug-eluting stent platform is based. Co-founder of several biomedical start-up companies (Angel Medical Systems, Svelte, Ostial Solutions, etc.), his honors include the Thorax Center Andreas Gruentzig Award for Inventor of the Year in 1997. Dr. Fischell has presented over 200 papers and authored more than 110 articles in peer-reviewed journals and 20 book chapters.
Kristine Canavan

VP, Regulatory and Quality

Kristine Canavan is an experienced regulatory and quality professional with a wealth of medical device and combination product experience. A Biomedical engineer by training, with an MPH in Biostatistics and Epidemiology, she has over 25 years of industry experience including several executive positions in regulatory, quality and clinical. She has actively managed products to market from early-stage product development efforts through the regulatory submissions and post-market activities. Kristine has held with Medtronic, Covidien and DePuy, in addition to several successful start-up companies.
Missy Broich

VP, Clinical Affairs

Missy Broich is an experienced clinical research professional with 20 years of experience in the Medical Device, Pharmaceutical and Biospecimen Industry. She began her career as a clinical research associate later advancing to director positions with companies such as National Marrow Donor Program, St. Jude Medical and several start-up companies. Missy received a BA degree in both Biology and Psychology from Coe College of Iowa. She has also held the CCRA distinction since 2010.

Board of Directors

Geoff Pardo

Partner, Gilde Healthcare
Chairman of the Board

Geoff Pardo joined Gilde Healthcare Partners in 2011 as a Partner, and has led investments in Inari Medical, Axonics Modulation Technologies (NASDAQ:AXNX), CVRx, Ablative Solutions, Inc., Inova Labs (sold to Resmed, Inc.), BionX (sold to Ottobock) and Vapotherm (NYSE: VAPO). He is currently a member of the Board of Directors at Inari, Axonics, Ablative Solutions, CVRx and Vapotherm.

Geoff also served as President & CEO of Facet Solutions, a spinal implant company focused on treating lumbar spinal stenosis until the company was sold to Globus Medical in 2011. Mr. Pardo began his career in medical devices as a product manager with Synthes USA (now J&J Depuy Synthes). Geoff has a B.A. from Brown University and an M.B.A. from the Wharton School of Business.
Paul Buckman

Chairman, NeuroOne

Paul Buckman has 39 years of medical device experience in general management, sales, marketing, finance, international and operations. Paul retired from LivaNova in 2023 and now serves as a Director on five medical device company boards. Prior to his role as President of North America with LivaNova, Paul was President of the Cardiovascular Divisions of both Boston Scientific and St. Jude Medical where he implemented significant growth strategies in both core and emerging technologies. He was also a co-founder, Chairman, and CEO of ev3 which was eventually sold to Covidien for $2.5B. Paul has also had previous CEO roles with Conventus Orthopaedics, SentreHeart, Pathway Medical (sold to Bayer Healthcare), and Devax (sold to Biosensors Intl.), in addition to executive management roles at DVI (sold to Eli Lilly) and American Hospital Supply. Presently, Paul serves as a Director on the Boards of NeuroOne (Chairman), Ablative Solutions, ActivOrtho, Inc. (Co-Founder), Helius Medical, and Shoulder Innovations.
David Fischell, PhD

Chairman and CEO, Angel Medical Systems

Dr. David Fischell is an inventor and serial entrepreneur who has co-founded 14 biomedical device companies in the last 25 years, including 5 active companies: Angel Medical Systems, eNeura, Inc (Chairman), NeuroPace, Inc., Svelte Medical Systems and Ablative Solutions (Director). After earning his Cornell Ph.D. in Applied Physics and Electrical Engineering, David joined Bell Laboratories in 1979 where, for 11 years, he performed and directed a wide range of research and development projects including leading an internal venture and the design and development of an integrated platform in the AT&T network for AT&T's first ever enhanced voice service, Infoworx TM. He left Bell Labs in 1991 to work full time on medical devices. He currently has 176 issued U.S. and has published numerous papers in the fields of telecommunications, cardiology and radiation dosimetry.

Dr. Fischell has received numerous awards and recognitions including his 1990 award for his design of the architecture of the AT&T network platform for enhanced voice services and election as a Fellow of the American Institute for Medical and Biological Engineering. He was elected to the Cornell University Board of Trustees in 2008 and the Weill Cornell Medicine Board of Overseers in 2016. He holds an appointment as adjunct professor, is chairman of the Advisory Council and was instrumental in the founding in 2004 of Cornell's Meing School of Biomedical Engineering.
John Kerschen

President and Managing Partner, Charter Capital Partners

John Kerschen has more than 30 years of financial experience in commercial banking, merger and acquisition advisory, and private capital investment. Since joining Charter Capital Partners in 1996, he has been responsible for more than 200 acquisition transactions with aggregate value of more than $2 billion. These transactions include diverse industries, such as manufacturing of metal parts, plastics, electronics, and medical products, as well as construction services, energy services, business services, and various distribution industries. John’s significant banking and financial background combined with his strong transaction management skills have been instrumental to Charter’s success over the years.
John is general partner and actively manages various investment funds including Charter Growth Capital Fund, a mezzanine debt and minority equity fund, Michigan Accelerator Fund I, an early stage VC fund as well as multiple other private equity investment entities. He is a current board member for Keystone Solutions, RimGuard, Ablative Solutions and Hastings Mutual Insurance Company and a board observer for Trice Medical and Swift Biosciences. John is a past board member for Grand River Aseptic Manufacturing, Intervention Insights, the Michigan Medical Device Accelerator and the national board for the Association for Corporate Growth.
John has attained FINRA securities registrations including the Series 79, 62, 63 and 65, and earned the Certified Valuation Analyst designation from the National Association of Certified Valuators and Analysts. He has a BA from Michigan State University and an MBA from DePaul University.
Louis Cannon, MD, FACA, FACC, FACP, FSCAI

Founder and Senior Managing Director, BioStar Capital and BioStar Ventures

Dr. Cannon is a past Judah Folkman Scholar in Residence and the Founder of BioStar Capital and BioStar Ventures now investing in Fund V. He is the past Founder and President of the Cardiac and Vascular Research Center of Northern Michigan and he has received recognition as one of “Americas Top Cardiologists” multiple years by the Consumers Research Council of America. He has served on the National Scientific or Medical Advisory Board or Speakers Bureau for Medtronic, Abbott, Boston Scientific, and Edwards Life Sciences, as well as other pharmaceutical or medical device companies from time to time. He is an innovator with patents previously licensed in the medical device field and has served on the BOD of Corindus Vascular Robotics (CVRS: NYSE ), CardioVascular Ingenuity, SETAGON, Amplitude Vascular Systems and REVA Medical. He has lectured and performed live cases throughout the word at the Montreal Heart Institute, Singapore, Japan and Paraguay where he performed one of the first trans -catheter aortic valve replacements in the world and later sold the BioStar company (AortX) to Hansen Medical. He is the co-moderator of the Shark Tank for medical devices sponsored by the CRF (The Columbia Research Foundation) and was the Founder and President of the Cardiac and Vascular Research Center in Northen Michigan.
Kate Rumrill

President and Chief Executive Officer

Kate Rumrill is a seasoned executive, with 30 years of extensive experience in the Medical Device and Pharmaceutical Industry. She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. Most recently, Kate was the President and CEO of NeoSync, Inc., a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with Covidien’s Peripheral Vascular Division. She has extensive experience in product development and new product launches, most notably through her time at Covidien and Eli Lilly & Company. Kate holds a BS degree in both Biology and Psychology from the State University of New York.
Nathan Harrington

Managing Partner, Philips Corporate Ventures

Nate Harrington joined Philips in 2011 and is a Managing Partner at Philips Corporate Ventures, responsible for its Image Guided Therapy (IGT) investments. He currently serves on over a half dozen of the portfolio’s boards; previous director positions include Corindus Vascular Robotics (CVRS) and Affera. Prior to moving to Philips Ventures in 2021, Nate was the Head of Business Development for the IGT business following the acquisition of Volcano and, in that capacity, oversaw acquisitions of Spectranetics, Cardioprolific, EPD, Vesper Medical and led investments in various start-ups currently in the IGT portfolio.
Prior to Philips, Nate worked over 8 years at Boston Scientific Corporation where he held various roles in both product management for Peripheral Interventions division and business development for the Cardiac Rhythm & Vascular group. Before BSC Nate spent 6 years in management consulting, half of them at Heath Advances focused on evaluating the commercial potential of emerging medical technology ranging from biotech and diagnostics to medical devices. Nate received his MBA from the Yale School of Management and his BA from Brown University.
Ron Bache

President and CEO of Bache, Inc

Ron Bache is the President and CEO of Bache, Inc. and an Operating Partner with Invus Opportunities. Bache was previously the President and CEO of AqueSys, Inc., a venture capital backed startup. AqueSys developed the XEN Gel Stent, the world’s first minimally invasive ab-interno surgical procedure for the leading cause of irreversible blindness, glaucoma. Bache joined AqueSys in 2009 while it was within a technology incubator and had just begun first in man trials. During his seven years as CEO, Ron spun the company out of the incubator, hired a full global team, raised $77 million in capital, patented multiple inventions, successfully executed an FDA clinical trial, obtained FDA clearance, obtained CE mark, created a CAT III code and obtained coverage from Medicare and private payers, and successfully commercialized globally. AqueSys was acquired by Allergan in 2015 for $300 million upfront plus milestones and Bache became a strategic advisor to Allergan for the next two years.
Prior to joining AqueSys, Ron was a Global Vice President at Advanced Medical Optics, the spinout of Allergan Surgical, and is now Johnson & Johnson Vision. Bache had marketing responsibility for the global refractive surgery business which included excimer lasers, custom wavefront guided and standard LASIK procedures, femtosecond lasers, wavefront abberrometers, multifocal intraocular lenses, phakic intraocular lenses, corneal inlays, and mechanical microkeratomes. During his tenure, AMO became the world’s #1 refractive surgery company through approximately $2 billion in acquisitions, partnerships, and internal R&D. Prior to AMO, Bache held commercial positions at Kraft General Foods, Johnson & Johnson (IOLAB Pharmaceuticals), Novartis (CIBA Ophthalmics), and Allergan Surgical.
Bache earned his Bachelor of Science in Business Administration from the University of Southern California and has completed executive education programs at Stanford and Harvard Business School.

We are proud to work with some of the most committed innovators in the industry.

Scientific Advisory Board (Global)

David E. Kandzari, MD

Director, Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta, Georgia

Michael Weber, MD, FACP, FACC, FAHA

Professor of Medicine at SUNY Downstate College of Medicine, Brooklyn, NY

Prof. Dr. med. Alexandre Persu

Head of the Hypertension Clinic Cardiology Department. Cliniques Universitaires Saint-Luc Université, Brussels, Belgium

Prof. Dr. med. Felix Mahfoud

Department of Internal Medicine and Cardiology, University Hospital of the Saarland, Germany

Prof. Atul Pathak

Head of Cardiology, Centre Hospitalier Princesse Grace Monaco

Prof. Dr. med. Roland E. Schmieder

Head of the Clinical Research Center (CRC), University   Hospital Erlangen, Germany